| Literature DB >> 36185298 |
Shuo Wang1, Xiao Yang1, Ziyi Yu1, Peng Du1, Yudong Cao1, Yongpeng Ji1, Jinchao Ma1, Yong Yang1.
Abstract
Purpose: To determine whether complete blood count (CBC) based inflammatory parameters can be used as markers predicting testicular germ cell tumors (TGCT). Material and methods: Between 2013 to 2018 the data of 58 patients with testicular TGCT undergoing radical orchiectomy and 54 malignancy-free healthy men were retrospectively analyzed as tumor group and control group. Patient baseline characteristics including age, pathological stage and pre-surgery CBC based inflammatory parameters including neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), lymphocyte/monocyte ratio (LMR), systemic immune-inflammation index (SII), lymphocyte ratio (LR), neutrophil ratio (NR), mean platelet volume (MPV) and red cell distribution width (RDW) were analyzed and compared between tumor group and control group. Receiver operating characteristic (ROC) curve were used analyzing data with significantly difference to assess the discriminative ability of the markers for TGCT, area under the curve (AUC), cut-off value, sensitivity and specificity were calculated. The binary logistic regression model was used to evaluate the association between significant inflammatory markers and risk of TGCT.Entities:
Keywords: germ cell tumors; inflammation; neutrophil/lymphocyte ratio; red cell distribution; systemic immune-inflammation index
Year: 2022 PMID: 36185298 PMCID: PMC9523471 DOI: 10.3389/fonc.2022.893877
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Demographic and clinicopathologic features of patients with testis tumor.
| Number | Seminoma | Non-seminoma | |||
|---|---|---|---|---|---|
| Immature Teratoma | Choriocarcinoma | Mix germ cell | |||
| Stage, n (%) | 58 | 35 | 9 | 3 | 11 |
| I | 28 (48.3) | 22 (62.9) | 3 (33.3) | 0 (0) | 3 (27.3) |
| II | 9 (15.5) | 6 (17.1) | 0 (0) | 1 (33.3) | 2 (18.2) |
| III | 21 (36.2) | 7 (20) | 6 (66.7) | 2 (66.7) | 6 (54.5) |
Figure 1Box-blot graphics of markers of NLR, SII and RDW for testis tumors and ctrl group. (A) NLR, (B) SII, (C) RDW. NLR, neutrophil/lymphocyte ratio; SII, systemic immune-inflammation index; RDW, red cell distribution.
Descriptive statics and comparison of CBC based parameters with respect to groups.
| Variables | Tumor group (n = 58) | Control group (n = 54) | P-value |
|---|---|---|---|
| Age (years) | 41.1 ± 15.36 | 44.89 ± 9.2 | 0.209 |
| NLR (%) | 3.79 ± 2.36 | 2.45 ± 1.4 | 0.005 |
| PLR (%) | 173.87 ± 62.9 | 157.68 ± 54.26 | 0.339 |
| LMR (%) | 4.11 ± 2.17 | 5.1 ± 2.11 | 0.616 |
| SII (%) | 870.39 ± 496.35 | 526.55 ± 263.64 | 0.001 |
| LR (%) | 24.35 ± 8.06 | 25.7 ± 9.8 | 0.533 |
| NR (%) | 68.04 ± 9.4 | 64.8 ± 10.7 | 0.184 |
| MPV (103/μL) | 9.86 ± 1.24 | 9.16 ± 1.82 | 0.062 |
| RDW (%) | 13.41 ± 1.2 | 12.83 ± 0.6 | 0.016 |
NLR, neutrophil/lymphocyte ratio; PLR, platelet/lymphocyte ratio; LMR, lymphocyte/monocyte ratio; SII, systemic immune-inflammation index; LR, lymphocyte ratio; NR, neutrophil ratio; MPV, mean platelet volume; RDW, red cell distribution; CBC, complete blood count.
Cut-off, AUC, sensitivity and specificity values of NLR, SII and RDW.
| Variables | AUC | Cut-off | Sensitivity | Specificity | 95% CI | P-value |
|---|---|---|---|---|---|---|
| Preop NLR | 0.704 | ≥ 3.38 | 51.4% | 88.6% | 0.581-0.826 | 0.003 |
| Preop SII | 0.725 | ≥ 881.24 | 45.7% | 91.4% | 0.608-0.842 | 0.001 |
| Preop RDW | 0.63 | ≥ 0.14 | 28.6% | 97% | 0.499-0.762 | 0.063 |
AUC, Area under the curve; NLR, neutrophil/lymphocyte ratio; SII, systemic immune-inflammation index; RDW, red cell distribution.
Figure 2Optimal cut-off values and ROC analyses for NLR (A), SII (B) and RDW (C). NLR, neutrophil/lymphocyte ratio; SII, systemic immune-inflammation index; RDW, red cell distribution; ROC, receiver operating characteristic.
Univariable and multivariable analyses for predicting testicular germ cell tumors.
| Univariable analysis | Multivariable analysis | |||||
|---|---|---|---|---|---|---|
| Tumor vs. Control | Tumor vs. Control | |||||
| OR | 95% CI | P value | OR | 95% CI | P-value | |
| NLR | ||||||
| <3.38 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||
| ≥3.38 | 4.5 | 1.52-13.30 | 0.007 | 5.86 | 1.67-20.65 | 0.006 |
| SII | ||||||
| <881.24 | 1 (Ref) | 1 (Ref) | 1 (Ref) | 1 (Ref) | ||
| ≥881.24 | 5.33 | 1.55-18.30 | 0.008 | 4.89 | 1.48-15.32 | 0.009 |
Ref, reference; NLR, neutrophil-lymphocyte ratio; SII, systemic immune-inflammation index.
Comparison of CBC based parameters between sTGCT and nsTGCT.
| Variables | sTGCT (n = 35) | nsTGCT (n = 23) | P-value |
|---|---|---|---|
| NLR (%) | 2.69 ± 1.36 | 2.95 ± 2.03 | 0.128 |
| PLR (%) | 165.97 ± 42.8 | 169.97 ± 53.16 | 0.258 |
| LMR (%) | 4.58 ± 1.88 | 4.99 ± 2.02 | 0.413 |
| SII (%) | 718.40 ± 289.25 | 629.65 ± 159.63 | 0.085 |
| LR (%) | 29.25 ± 7.85 | 24.37 ± 6.82 | 0.234 |
| NR (%) | 67.94 ± 8.13 | 65.18 ± 12.37 | 0.194 |
| MPV (103/μL) | 9.34 ± 2.14 | 9.56 ± 1.92 | 0.192 |
| RDW (%) | 14.41 ± 1.31 | 11.92 ± 1.26 | 0.116 |
NLR, neutrophil/lymphocyte ratio; PLR, platelet/lymphocyte ratio; LMR, lymphocyte/monocyte ratio; SII, systemic immune-inflammation index; LR, lymphocyte ratio; NR, neutrophil ratio; MPV, mean platelet volume; RDW, red cell distribution; CBC, complete blood count; sTGCT, seminomatous testicular germ cell tumors; nsTGCT, non-seminomatous testicular germ cell tumors.
Distribution of descriptive properties and comparison of Clinical parameters between the patients with respect to NLR <3.38 and ≥3.38, SII<881.24 and ≥881.24.
| Variables | NLR<3.38 (n = 31) | NLR≥3.38 (n = 27) | P value | SII<881.24 (n = 34) | SII≥881.24 (n = 24) | P-value |
|---|---|---|---|---|---|---|
| Ages (years) | 33.6 ± 9.8 | 45.1 ± 14.8 | 0.011 | 37.16 ± 14.17 | 42.25 ± 13.11 | 0.281 |
| Stage, n (%) | 0.034 | 0.049 | ||||
| IA, B, S | 19 (61.3) | 9 (33.3) | 20 (58.8) | 8 (33.3) | ||
| II+III | 12 (38.7) | 18 (66.7) | 14 (41.2) | 16 (66.7) |
NLR, neutrophil/lymphocyte ratio; SII, systemic immune-inflammation index.
Comparison of NLR, SII in present study with traditional biomarkers and miR markers reported by other studies.
| Variables | NLR | SII | AFP, HCG, LDH | miR-371-3p | miR-372-3p | miR-373-3p |
|---|---|---|---|---|---|---|
| Predicting role in TGCT | Yes | Yes | Yes | Yes ( | Yes ( | Yes ( |
| Sensitivity (%) | 51.4% | 45.7% | AFP:13.6-47.1% ( | 70.8-88.7% ( | 82-87.5% ( | 59% ( |
| Specificity (%) | 88.6% | 91.4% | NA | 93.4-99% ( | 65-94% ( | 91% ( |
| Markers’ level decreased after orchiectomy | No | Yes | Yes ( | Yes ( | Yes ( | Yes ( |
| Consistent in fluids and tissues | NA | NA | NA | Yes [2,3] | Yes [2,3] | Yes [2,3] |
| Stages distinguish | Yes | Yes | Yes [1] | Yes ( | NA | Yes ( |
| Histological distinguish between sTGCT and nsTGCT | No | No | Yes [1] | Yes ( | NA | NA |
| Specific expressed in TGCT | No [4] | No [5,6] | No [1] | Yes ( | Yes ( | Yes ( |
NA, not applicable; TGCT, testicular germ cell tumors; sTGCT, seminomatous testicular germ cell tumors; nsTGCT, non-seminomatous testicular germ cell tumors.
1Paolo Pedrazzoli, Giovanni Rosti, Elenora Soresini, et al. Serum tumour markers in germ cell tumours: from diagnosis to cure. Crit Rev Oncol Hematol. 2021, 159:103224.
2Almstrup K, Lobo J, Morup N, et al. Application of miRNAs in the diagnosis and monitoring of testicular germ cell tumours. Nat Rev Urol. 2020;17:201-203.
3Lobo J, van Zogchek MJ, Nuru MG, et al. Combining hypermethylated RASSF1A detection using ddPCR with miR-371a-3p testing: an improvement panel of liquid biomarkers for testicular germ cell tumor patients. Cancer (Basel). 2021, 13:5228.
4Wang S, Ji Y, Chen Y, et al. The values of systemic immune-inflammation index and neutrophil-lymphocyte ratio in the localized prostate cancer and benign prostate hyperplasia: a retrospective clinical study. Front Oncol. 2022, 11:812319.
5Kao SC, Pavlakis N, Harvie R, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognostic in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res. 2010, 16:5805-5813.
6Viers BR, Boorjian SA, Frank I, et al. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Eur Urol. 2014, 66:1157-1164.